Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The end goal is to put valuable drugs on the market. The moment we receive 3rd party validation ipix becomes 100x stronger than today.
Many investors are waiting for that day to cut risk and will again jump in.
Money in the bank and Having BP or Bio partners helping with formulations and trials will move these drugs so much faster. IMO.
Big money will squash the traders and suck up anything being flipped. Cheers to that day
Hopefully that is 25k in ipix pocket from Aspire. Load up the cash
PHENOMENAL POST. Thank you for taking time to piece those PRs together. Stickie please.
I would not mind seeing a great power hour on anticipation of a week end deal. Powerful meetings occurred this week at the conference and they announced the term sheet last week prior to the meetings. That is good leverage
Who has those IBD market numbers? Please repost for new eyes. Crohns Disease alone was at 9 billion in 2016 and expected to increase to 13-14 billion by 2026
UC is approx 7.5 billion
So ipix for these 2 indications can crack into a 20 BILLION market.
Oral B for CD and UC will be the largest milestone in IPIX history Dud. We would be talking north of 5 billion a year if it works and is safe.
It would be the most valuable indication in ipix pipeline......up until K becomes oral
Guaranteed. I know and know wherr
Only you can spin it like that. Lol. Or maybe Max too.
Good luck this weekend.
Thanks for clarification on GI and Mucositis.
2 mil baby. Half way thru! Next step up baby!!! Next stop .60
I wonder if this PR was signed off by the possible partner?
Or does this PR now light a fire under other negotiations?
We will see
Solidify smallest market indication first. This will build strength for IPIX! Then once we have strength and a reasonable market cap.....ipix will deal OM the closest to market for much higher. IMO
A deal can hit the wires any day
Imo! The big buyer was a leak on this signed term and I’m hopeful ipix executes this term Sheet.
Well the bidder for both was maybe too low so move in to next. This could allow more power for big negotiations on OM
The OM is a separate deal we will hear about soon. We should see a Kevetrin one coming as well. Light em up
Innovation Pharmaceuticals Announces Non-Binding Term Sheet Signed with Global Pharmaceutical Company to Develop and Commercialize Brilacidin for the Treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis
BEVERLY, MA – May 16, 2019 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has signed a non-binding term sheet with a global pharmaceutical company to develop and commercialize locally-administered Brilacidin (e.g., foam, enema, gel), on a worldwide basis, for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis.
The non-binding term sheet also includes a Right of First Refusal for rights to Brilacidin for the treatment of more extensive forms of Inflammatory Bowel Disease, such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for rights to Brilacidin in other Gastrointestinal (GI) indications.
Completion of the transaction, as specified in the non-binding term sheet, is subject to further negotiation and execution of a definitive agreement. If the definitive agreement is reached and signed, the Company anticipates that it would receive an upfront payment, plus potential additional regulatory and commercial milestone payments, as well as royalties.
First Refusal for rights on UC and Crohns......and then First Negotiation Rights for all other GI!
Very detailed and what I was hoping. To offset the current deflated value....ipix is throwing in first rights! I figured that was the plan
I bought those! Thanks.
Lively it is. Great volume. Could this be round 2 of last weeks buyer.
Severe Oral Mucositis needs B! As the HPV virus is adding more HN cancer yearly this is a must. Please help all the sufferers.
Race Heats Up for a Blockbuster Oral Mucositis Drug; Look Now Before Wall Street Catches On
https://www.wallstreetpr.com/race-heats-up-for-a-blockbuster-oral-mucositis-drug-look-now-before-wall-street-catches-on-41336
Negotiations are with multiple suitors. Phase 3 is the most important next step for OM. Blue Sky market opp! This is what I know
We can use Aspire as of Jan 10 2019. I bet that was the rally killer at .43. Hopefully ipix got some cash in the .30’s!
2million volume! Yes sir. We saw this go from .12 to .40 on one small buyer group. W no news. This will fly on real deal news. Give us a tidbit in the q Leo!
Go Ipix!!!
Love the volume.
It would be a perfect play if Leo executed. Share price rises! CTrader brings the shorts - release new funding deal - allow shorts to get more dirty.....then! Release a monster deal to crush them.
Lol
Now that! I would love to see
What’s the GOAL here? Link up with a partner(s) to validate and fund B-OM phase 3 into a 600 million -1.2 billion a year indication.
Once that goal hits....we move K and IBD and Derma
10-Q and deal watch this afternoon
This is good. Money is good for a non rev bio. Weren’t you screaming March 31st the lights were out? Lol. Now we have much more time to ink a deal.
I think someone or group wanted IPIX and at whatever price in a short period of time. From .12 to .43 how many shares took us there? Whomever wanted them took it up.
So why? Why not gracefully add over weeks or months in our .12-.15 channel?
It will be interesting to see what news and when news coincides with whomever wanted in badly!
I’m hoping someone knew something and it will be released tomorrow afternoon a few hours short of eod and then post the 10-Q after hours.
IMO MGMT has learned a deadline is best to be given to suitors regarding a deal. Maybe the 10Q release was that deadline. Crap or get off the pot verbiage. Maybe someone took a hefty one this time
I see .291 currently? Is that what you see? I’d say that is a big jump from the channel we sat in for a long time. Jmo. So it’s not anywhere close to where we started.
And we’ve seen 8 million plus traded in the 30 range which is good volume for ipix.
I’d say we had an eager group who wanted ipix very badly. For what reason? I think we find out this month.
10Q - Deal watch! Starts now
Exactly. No one knows.
I just enjoy the volume at much higher rates
Setting a base for next climb and hoping for a deal which is more of an elevator not climb.
Friday 2PM partner release :). Leo listens to me......
Watching L2...quick short and almost a million in volume. This will rip soon to .60 / .80
Great PR and then follow up shareholder letter. Now......we need a partner to come out and validate those big numbers and expectations. 600 million to 1.2 billion in sales in first 3 years. For basically our smallest indication on the books!!! IBD and 50% of all cancers on tap.
The top will shatter.
Blue Sky’s.
http://www.ipharminc.com/press-release/2019/4/23/innovation-pharmaceuticals-jama-article-reinforces-need-for-novel-oral-mucositis-treatments-in-supportive-cancer-care
Based on our preliminary estimates, the total Brilacidin oral mucositis market opportunity in Head and Neck Cancer annually in the U.S. and Europe would be approximately $600 million to $1.2 billion.
In follow-up to today’s Press Release, the Company wanted to provide shareholders with additional perspectives on the competitive positioning and market opportunity of Brilacidin oral rinse for use in Head and Neck Cancer (HNC) patients undergoing chemoradiation. Compared to other oral mucositis (OM) drug candidates being evaluated in clinical testing, Innovation Pharmaceuticals believes its drug candidate, Brilacidin oral rinse, occupies a leadership position as preparations move forward for its planned Phase 3 program. Most potential competitor drug candidates target minimizing symptoms and not prevention, and/or are disadvantaged by not having as patient-friendly modes of delivery (IV) in comparison to our easily-administered oral rinse. For detailed comparative analysis, please see our Company blog post on the topic, linked below:
http://www.ipharminc.com/new-blog/2018/9/24/brilacidin-for-oral-mucositis-at-a-glance-comparative-data-presentation-with-other-investigational-om-drugs
Market Opportunity (HNC-Only, US and Europe)
According to published statistics, and based on other data sources, oral mucositis accompanies chemoradiation treatment in almost all Head and Neck Cancer patients undergoing treatment. The annual incidence of HNC in the US and Europe is approximately 150,000 (worldwide approximately 750,000 cases). Approximately 60 to 70% of these patients will develop Severe Oral Mucositis (SOM) (WHO Grade > 3) (confirmed in our own clinical study). Because it cannot be predicted which patients will get SOM, all patients would begin Brilacidin as soon as starting chemoradiation and continue until completion (typically a seven-week course). Given that Brilacidin is administered as a convenient and patient-friendly oral rinse (swish and spit, 3x daily), we believe that our market penetration could realistically approach 80 percent within the first three years following market introduction. This would translate into a targeted 120,000 treated HNC patients in the U.S. and Europe per year according to the anticipated label indication. Moreover, following regulatory approval in HNC, we would anticipate the potential to expand the label to capture a broadened market—patients experiencing OM across various cancer indications, estimated to include as many as 650,000 people annually (25% to 60% of all cancer patients receiving chemotherapy experience OM).
We believe most other competitor products in development, with less patient-friendly modes of delivery (e.g., IV), would be less able to reach this broader OM market. An additional factor that should help to expedite market adoption of Brilacidin oral rinse includes the potential to avoid incremental inpatient costs incurred in those SOM patients requiring hospitalization, estimated to be between $18,000 and $25,000 per incident. Private and government payers would thus be incentivized to adopt preventative treatment due to large potential cost-savings. We anticipate being able to price Brilacidin at $5,000 to $10,000 per full course of treatment based on the large unmet need as well based on initial pricing for the only other OM drug ever approved (Palifermin, hematopoietic stem cell transplantation, HSCT). Based on our preliminary estimates, the total Brilacidin oral rinse market opportunity annually in the U.S. and Europe would be approximately $600 million to $1.2 billion.
For additional insight into the Brilacidin market opportunity for oral mucositis, refer to additional Company blog posts, linked below:
60K hit in final minutes...real strong in final 10 minutes. No news.
Let’s enjoy this ride back up longs. We have given shelter long enough. Time to pass in the dust. $$$$
Agree. Something is going on
About 300 k ASK SLAPPING END OF DAY?
I see .417? Close
Nm. Now .38